Cited by 725Telomeres, Telomerase, and SenescenceBlood disorders and treatmentsAcute Myeloid Leukemia Research

Mutations in TERT, the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia

Open access
Yamaguchi, Hiroki, Calado, Rodrigo T., Ly, Hinh, Kajigaya, Sachiko, Baerlocher, Gabriela M., Chanock, Stephen J., Lansdorp, Peter M., Young, Neal S.·2005·New England Journal of Medicine

Abstract

BACKGROUND: Mutations in TERC, the gene for the RNA component of telomerase, cause short telomeres in congenital aplastic anemia and in some cases of apparently acquired hematopoietic failure. We investigated whether mutations in genes for other components of telomerase also occur in aplastic anemia. METHODS: We screened blood or marrow cells from 124 patients with apparently acquired aplastic anemia and 282 control subjects for sequence variations in the TERT, DKC1, NHP2, and NOP10 genes; an additional 81 patients and 246 controls were examined for genetic variations in TERT. Telomere lengths and the telomerase activity of peripheral-blood leukocytes were evaluated in patients carrying genetic variants. Identified mutations were transfected into telomerase-deficient cell lines to examine their effects and their mechanism of action on telomerase function. RESULTS: Five heterozygous, nonsynonymous mutations (which cause an amino acid change in the corresponding protein) were identified in TERT, the gene for the telomerase reverse transcriptase catalytic enzyme, among seven unrelated patients. Leukocytes from these patients had short telomeres and low telomerase enzymatic activity. In three of these patients, the mutation was also detected in buccal mucosa cells. Family members carrying the mutations also had short telomeres and reduced telomerase activity but no evident hematologic abnormality. The results of coexpression of wild-type TERT and TERT with aplastic anemia-associated mutations in a telomerase-deficient cell line suggested that haploinsufficiency was the mechanism of telomere shortening due to TERT mutations. CONCLUSIONS: Heterozygous mutations in the TERT gene impair telomerase activity by haploinsufficiency and may be risk factors for marrow failure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa042980

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with aplastic anaemia and shorter telomeres at diagnosis show more severe disease, poorer response to treatment, increased risk of relapse and MDS, and lower survival.

    “Patients with shorter telomeres at diagnosis show a more severe disease, a poorer response to treatments, an increased risk of relapse and development of myelodysplastic syndrome (MDS; see below) and a lower survival rate75,80,81.”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [75]

    The introductory passage reports short telomeres in patients with acquired aplastic anemia, especially those who do not respond to immunosuppressive therapy; the discussion also notes poor response among patients with TERT mutations. The paper does not establish that telomere length at diagnosis predicts disease severity, relapse, development of MDS, or survival. Its treatment-response evidence is narrower than the full claim. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Around 9% of patients with acquired aplastic anaemia carry mutations in TERC, TERT and DKC1, which are also mutated in inherited aplastic anaemia such as dyskeratosis congenita.

    “Around 9% of patients with acquired aplastic anaemia carry mutations in the telomerase components TERC, TERT and DKC1, which are also mutated in inherited aplastic anaemia, as in dyskeratosis congenita74,75.”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [75]

    The Mutations section (page not provided) reports TERC mutations in 5 of 205 patients and TERT mutations in 7 of the remaining 200—12 of 205 overall, or about 6%, rather than 9%. It explicitly reports no DKC1 mutations in the patients studied. The background section (page not provided) does link DKC1 and TERC mutations to dyskeratosis congenita. (LLM, conf=0.89)

    Experimental — accuracy not yet measured
  • About one-third of patients with aplastic anaemia show short telomeres in peripheral blood, suggesting a causative link between aplastic anaemia pathology and telomere dysfunction.

    “About one-third of patients with aplastic anaemia show short telomeres in peripheral blood, which suggests that there is a causative link between aplastic anaemia pathology and telomere dysfunction75,76,79.”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [75]

    The paper’s introductory passage (indexed under Abstract; page unavailable) says that approximately one third of patients with *acquired* aplastic anemia have short telomeres in leukocytes, especially those who do not respond to immunosuppressive therapy. Its conclusion says TERT mutations impair telomerase activity and may be risk factors for marrow failure, supporting the suggested link. The citing sentence omits the restriction to acquired aplastic anemia and thus states the one-third figure for a broader population. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Because losing function of a single TERT or TR allele is enough to impair telomere maintenance, these mutations follow autosomal-dominant inheritance.

    “They manifest in an autosomal-dominant inheritance pattern because complete or partial loss-of-function of one allele is sufficient to perturb telomere maintenance38,39,41.”

    From The telomere syndromes (2012) · cites this paper as [41]

  • Between 3% and 5% of aplastic anaemia patients have mutations in TERT or TR.

    “In addition, 3–5% of aplastic anaemia patients carry mutant TERT and TR genes41,72,73.”

    From The telomere syndromes (2012) · cites this paper as [41]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Alter BP. Inherited bone marrow failure syndromes: introduction. In: Young NS, Alter BP, eds. Aplastic anemia, acquired and inherited. Philadelphia: W.B. Saunders, 1994:271-4.
  2. Pogacic V, Dragon F, Filipowicz W. Hu- man H/ACA small nucleolar RNPs and telo- merase share evolutionarily conserved pro- teins NHP2 and NOP10. Mol Cell Biol 2000; 20:9028-40.

Cited by

Sorted by citations

Authors
Yamaguchi, H., Calado, R. T., Ly, H., Kajigaya, S., Baerlocher, G. M., Chanock, S. J., Lansdorp, P. M., & Young, N. S.
Affiliations
  • National Institutes of Health (US)
  • National Heart, Lung, and Blood Institute (US)
  • Emory University (US)
  • Terry Fox Research Institute (CA)
  • University of British Columbia (CA)
Venue
New England Journal of Medicine
Published
2005-04-07
Volume
352
Issue
14
Pages
1413-1424
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2037236933
Cited by
723
References
52
Citations by year
2026: 14 · 2025: 12 · 2024: 27 · 2023: 23 · 2022: 26 · 2021: 21 · 2020: 27 · 2019: 28 · 2018: 28 · 2017: 39 · 2016: 23 · 2015: 37 · 2014: 49 · 2013: 44 · 2012: 32
FWCI
30.18
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Blood disorders and treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
TERT mutation, telomerase reverse transcriptase, aplastic anemia, telomere shortening, haploinsufficiency, telomerase activity, DKC1, NHP2, NOP10, hematopoietic failure, non-synonymous mutations, leukocytes
MeSH terms
Adult, Aged, Anemia, Aplastic, Bone Marrow Cells, DNA Mutational Analysis, DNA-Binding Proteins, Female, Heterozygote, Humans, Male, Middle Aged, Mutation, Risk Factors, RNA, Gene Expression, Case-Control Studies, Polymerase Chain Reaction, Telomere, Telomerase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review